Menu
A leading digital healthcare company
Fibronostics is a leader in the development of artificial intelligence based noninvasive diagnostics. We are focused on metabolic diseases that affect the liver and kidney.
Our lead product, LIVERFAStTM provides physicians and patients valuable information about fibrosis, activity and steatosis of the liver based on common blood biomarkers.
LIVERFAStTM is used for patient identification, screening and monitoring of chronic liver diseases like NASH and NAFLD.
LIVERFAStTM uses 10 common blood biomarkers combined with cutting edge neural network AI to deliver insights that are equivalent to biopsy without the cost, pain, and complications.
LIVERFASt™ assess liver fibrosis, activity & steatosis of NAFLD and NASH patients
We help doctors and health care systems identify patients that have or are at risk of having NAFLD or NASH so that they can be treated earlier and better.
Noninvasive and easy to do, we give doctors and patients the information they need to stage the severity of a patient’s liver damage fast and early.
Regular surveillance of treatment for progression with easily repeatable noninvasive tests enables optimized disease management.
Fibronostics is a leader in the development of artificial intelligence based noninvasive diagnostics. We are focused on metabolic diseases of the liver and kidney.
Fibronostics is a healthcare technology company focused on transforming non-invasive solutions for early disease intervention.
© 2022, Fibronostics, All Rights Reserved.
© Copyright Fibronostics. All Rights Reserved